Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
NCT07592546 on ClinicalTrials.gov · last registry update 2026-06-26
An unusually large phase 4: 240 participants, more than double the 72 typical for the stage. Due to report 1 December 2028, alongside 16 other tracked readouts that quarter. Primary outcome, as filed: Serum C-reactive Protein (CRP). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Alain Dagher
- Sponsor type
- Other
- Enrollment
- 240
- Started
- 2026-08-01
- Primary completion
- 2028-12-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Serum C-reactive Protein (CRP)
Conditions studied
Class I/II Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.